Korea Continuous Glucose Monitoring Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The korea continuous glucose monitoring market size reached USD 233.98 million in 2026 and is forecast to reach USD 468.17 million by 2031 at a 2026-2031 CAGR of 14.88%. This report is Segmented by Component (sensors, Durables Comprising Receivers and Transmitters), by End User (hospitals/Clinics, Home/Personal), and by Demography (adult, Pediatric), With Market Forecasts Provided in Terms of Value (USD Million).

Korea Continuous Glucose Monitoring Devices Market Trends and Insights

Reimbursement Expansion Under Korea's National Health Insurance (NHIS)

Policy support serves as an immediate catalyst, reducing out-of-pocket costs for priority groups and encouraging continuous sensor use. Coverage improvements have coincided with a marked age gradient in uptake, with national cohort data showing higher continuous use among younger individuals and lower use among older adults who face more barriers to adoption. Clinical societies have updated guidance in favor of real-time CGM for all adults with Type 1 diabetes and for those with Type 2 diabetes who require intensified insulin therapy, which aligns clinical practice with payer objectives to prevent severe hypoglycemia and improve time in range. Economic evaluations conducted in South Korea find that real-time CGM is cost-effective in insulin-intensive Type 2 diabetes, which informs coverage evaluations and underscores the budget impact of fewer acute complications. The reimbursement review process also emphasizes device quality and safety, which means vendors need to provide robust clinical evidence and comply with local submission standards to sustain funding. Over time, streamlined implementation and education will remain essential so that policy improvements translate into continuous real-world usage among eligible patients.

Rapid Uptake Of CGM-Enabled Artificial‐Pancreas Research Programs

Automated insulin delivery systems are bringing CGM into more care pathways by linking sensors, pumps, and algorithms into closed-loop operation. Standards of care for 2026 recommend AID for adults with Type 1 diabetes and recognize the role of CGM within comprehensive insulin management, which supports clinical and payer alignment around these platforms. Korean guidelines also elevate real-time CGM in Type 1 diabetes and define best practices for integrating sensor data into dose titration, which underpins training protocols in tertiary hospitals. Domestic R&D programs continue to explore device integration and data-driven dose guidance, which may widen AID benefits beyond pump users to multiple daily injection cohorts. As algorithms mature, hospital adoption and home use reinforce each other because the same sensor platforms support both inpatient and outpatient workflows.

Monopolized Import Channel & High Device ASPs

Device affordability remains a barrier for users who do not qualify for higher reimbursement or who face budget constraints. Domestic manufacturing capacity is expanding, which can lower landed costs and shorten supply lines for sensors and receivers. Cost-utility research in South Korea supports funding for intensive insulin users, yet patients outside prioritized groups still weigh ongoing sensor costs against limited budgets. Uptake patterns confirm that continuous use is higher among younger and more digitally engaged cohorts, and lower among older adults who are more sensitive to recurring expenses and required device training. As local vendors improve scale and as reimbursements evolve, price dispersion can narrow and help the South Korea continuous glucose monitoring market reach new patient segments. In the meantime, clinicians and payers continue to target groups that derive the greatest clinical and economic benefits from continuous use.

Other drivers and restraints analyzed in the detailed report include:

• Growing Demand From Type-2 Diabetics On GLP-1 Therapy
• Next-Gen Multi-Analyte (Glucose + Ketone) Sensors Entering KMFDS Trials
• Physician Scepticism Over Non-Adjunctive Use In Primary Care

Segment Analysis

Sensors account for the largest component share, with 76.78% in 2025, driven by recurring replacement cycles and widespread clinical endorsement for real-time monitoring. Advances in accuracy and reduced calibration have raised patient confidence, while app-based analytics improve visibility into trends that inform therapy adjustments. Clinical guidance has clarified how to use time-in-range metrics to guide treatment, which further legitimizes the role of sensors in standardized care pathways. Domestic vendors have launched calibration-free platforms with competitive MARD and faster warm-up, which strengthen local value propositions and support broader uptake across age groups. As these features consolidate into baseline expectations, competition moves toward wear comfort, seamless data sharing, and compatibility with clinical dashboards that fit into hospital and clinic workflows.

Durable components, including receivers and transmitters, are expanding at the fastest clip with a 16.86% CAGR. User preferences vary by age and setting because some cohorts favor smartphone-native monitoring while others need dedicated displays for simplicity and accessibility. Closed-loop systems validate the role of reliable communication hardware that can sustain high-frequency data exchange for algorithmic control, which helps define performance benchmarks for the category. Domestic offerings of receivers and app updates also reflect attention to localization, language, and user-interface design, which encourages adoption in older adults who need straightforward displays. As platforms converge on accuracy, the South Korea continuous glucose monitoring industry is differentiating on ecosystem depth, app usability, and the quality of integration with hospital systems.

Complete Report Scope:

• By Component
  • Sensors
  • Transmitters
  • Receivers
• By End User
  • Hospitals / Clinics
  • Home / Personal
• By Demography
  • Adult
  • Pediatric

List of Companies Covered in this Report:

• Abbott Laboratories
• Dexcom
• Medtronic
• i-SENS Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support